DHSC (UK) · Jul 9, 2026
Guidance: Physical activity guidelines: early years (under 5s)
Infographic explaining the physical activity needed for general health benefits for children under 5 years of age.
Global Health · page 10
UK, EU & international health agencies
DHSC (UK) · Jul 9, 2026
Guidance: Physical activity guidelines: pregnancy and after childbirth
Infographics explaining the physical activity needed for general health benefits for women in pregnancy and after giving birth.
DHSC (UK) · Jul 9, 2026
Guidance: Physical activity guidelines: adults and older adults
Infographic explaining the physical activity needed for general health benefits for adults and older adults.
DHSC (UK) · Jul 9, 2026
Guidance: Physical activity guidelines: UK Chief Medical Officers' report
A report from the Chief Medical Officers in the UK on the amount and type of physical activity people should be doing to improve their health.
UKHSA (UK) · Jul 9, 2026
Accredited official statistics: Monthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, October 2026 to October 2027
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): October 2026 to October 2027.
UKHSA (UK) · Jul 9, 2026
Accredited official statistics: Monthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, September 2026 to September 2027
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): September 2026 to September 2027.
UKHSA (UK) · Jul 9, 2026
Accredited official statistics: Monthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, August 2026 to August 2027
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): August 2026 to August 2027.
UKHSA (UK) · Jul 9, 2026
Accredited official statistics: Monthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, July 2026 to July 2027
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): July 2026 to July 2027.
UKHSA (UK) · Jul 9, 2026
Accredited official statistics: Monthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, June 2026 to June 2027
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): June 2026 to June 2027.
UKHSA (UK) · Jul 9, 2026
Accredited official statistics: Monthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, May 2026 to May 2027
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): May 2026 to May 2027.
UKHSA (UK) · Jul 9, 2026
Accredited official statistics: Monthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, April 2026 to April 2027
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): April 2026 to April 2027.
UKHSA (UK) · Jul 9, 2026
Accredited official statistics: Monthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, March 2026 to March 2027
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): March 2026 to March 2027.
UKHSA (UK) · Jul 9, 2026
Accredited official statistics: Monthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, February 2026 to February 2027
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): February 2026 to February 2027.
UKHSA (UK) · Jul 9, 2026
Accredited official statistics: Monthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, January 2026 to January 2027
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): January 2026 to January 2027.
UKHSA (UK) · Jul 9, 2026
Accredited official statistics: Monthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, December 2025 to December 2026
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): December 2025 to December 2026.
UKHSA (UK) · Jul 9, 2026
Accredited official statistics: Monthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, November 2025 to November 2026
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): November 2025 to November 2026.
DHSC (UK) · Jul 9, 2026
Corporate report: NHS Resolution annual report and accounts: 2025 to 2026
Annual report and accounts from NHS Resolution covering 1 April 2025 to 31 March 2026.
UKHSA (UK) · Jul 9, 2026
Corporate report: UK Health Security Agency (UKHSA) research involving animals
UKHSA and Porton Biopharma Limited have committed to being more transparent with the public about when, how and why we use animals in research.
UKHSA (UK) · Jul 9, 2026
Guidance: Crimean-Congo haemorrhagic fever (CCHF) contact tracing matrix
How to classify and manage people who have been exposed to CCHF.
UKHSA (UK) · Jul 9, 2026
Guidance: Marburg and Ebola contact tracing matrix
How to classify and manage people who have been exposed to Ebola disease or Marburg virus disease.
MHRA (UK) · Jul 9, 2026
Access, new active substance and biosimilar work sharing initiatives
Information on applying for New Active Substance Work Sharing Initiative (NASWSI) and Biosimilar Work Sharing Initiative (BSWSI) assessments and list of approved products.
DHSC (UK) · Jul 9, 2026
Corporate report: Health Research Authority annual report and accounts 2025 to 2026
The report explains what the Health Research Authority (HRA) does, what it achieved and some of the challenges it faced in 2025 to 2026.
UKHSA (UK) · Jul 9, 2026
Accredited official statistics: Annual epidemiological commentary: Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections, up to and including financial year 2026 to 2027
Trends in MRSA, MSSA, E. coli, Klebsiella spp. and P. aeruginosa bacteraemia and C. difficile infection by financial year.
UKHSA (UK) · Jul 9, 2026
Accredited official statistics: Quarterly Epidemiological Commentary: mandatory MRSA, MSSA and Gram-negative bacteraemia and Clostridioides difficile infection, data up to April to June 2027
Epidemiological analyses of mandatory surveillance data on healthcare associated infections (HCAI); MRSA, MSSA and Gram-negative bacteraemia (Escherichia coli (E. coli), Pseudomonas aeruginosa ( P. aeruginoa), Klebsiella species (Klebsiella spp.)), and Clostridioides difficile (C. difficile) infection.